Innovation: Intelligent bacteria demonstrate high efficacy in the treatment of widespread disease irritable bowel syndrome with typical symptoms of recurrent diarrhoea, abdominal pain, bloating and constipation
Por un escritor de hombre misterioso
Descripción
New therapy with unique bacterial strain B. bifidum HI-MIMBb75 promises help for approximately 80 million Europeans suffering from irritable bowel syndrome1 World's largest clinical OTC irritable bowel syndrome trial investigating the efficacy of this particular strain published in the renowned medical journal The Lancet Gastroenterology & Hepatology2 Results show significant efficacy for all predominant irritable bowel syndrome symptoms and all subtypes while simultaneously improving patients’ quality of life2 (Gräfelfing/Munich, Germany) The world's largest OTC irritable bowel syndrome (IBS) trial comes up with remarkable results, which were recently published in the renowned medical journal The Lancet Gastroenterology & Hepatology. For the first time, leading German scientists around Prof. Dr. Peter Layer (Israelitic Hospital Hamburg) were able to prove the significant efficacy of a heat-inactivated bacterial strain on patients with IBS. Trial results show that B. bifidum HI-MIMBb75
Nutrients, Free Full-Text
Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery
CPhI worldwide: German probiotics company SYNformulas seeks partnerships to drive
1211_article_01
Cilansetron - New Treatment for IBS - Clinical Trials Arena
Irritable Bowel Syndrome
Probiotic management and inflammatory factors as a novel treatment in cirrhosis: A systematic review and meta-analysis
Irritable bowel syndrome - The Lancet
Cureus, Intestinal Spirochetosis and Chronic Diarrhea: A Case Report and Literature Review
de
por adulto (el precio varía según el tamaño del grupo)